Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026452 | 0.91 | ALDH1A1 (0.40) | ALDH1A1GAAKMT2AMEN1CYP2C9 | |
| SCHEMBL4772648 | 0.88 | KIF11 (0.44) | ALDH1A1KIF11KMT2AMEN1LMNA | |
| SCHEMBL4021692 | 0.88 | ALDH1A1 (0.38) | ALDH1A1GAAKIF11KMT2AMEN1 | |
| SCHEMBL4779411 | 0.88 | MC4R (0.34) | ALDH1A1GAAKMT2AMEN1CYP2C9 | |
| SCHEMBL4021786 | 0.87 | ALDH1A1 (0.42) | ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4779404 | 0.87 | MCHR1 (0.34) | ALDH1A1GAAKIF11KMT2AMEN1 | |
| SCHEMBL4779421 | 0.87 | MCHR1 (0.34) | ALDH1A1GAAKIF11KMT2AMEN1 | |
| SCHEMBL4022116 | 0.86 | CYP2C9 (0.41) | ALDH1A1GAAKMT2AMEN1CYP2C9 | |
| SCHEMBL4022953 | 0.84 | ALDH1A1 (0.39) | ALDH1A1GAAKMT2AMEN1CYP2C9 | |
| SCHEMBL4022948 | 0.84 | ALDH1A1 (0.39) | ALDH1A1GAAKMT2AMEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | ALDH1A1 258/4885GAA 350/4885KIF11 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.